Stanford Z944 Treatment Study - Kitzerow Attribution Rubric
Stanford Converging Evidence Report Card
This report evaluates Stanford’s Z944 intervention targeting excitatory/inhibitory imbalance in the reticular thalamus within the cortico-striatal-thalamic loop. Scoring is based on temporal precedence, dissemination gap, publication timeline, exposure likelihood, structural specificity, and institutional response.
Intellectual Property and Attribution
What the protected work is and which potential concerns this report evaluates.
Trademark Infringement
Unauthorized use of Kitzerow’s protected names or confusingly similar marks in a way that may create confusion about source, sponsorship, or affiliation.
Copyright Infringement
Unauthorized copying of protected expression or qualifying original selection, coordination, and arrangement within the compilation.
Plagiarism or Attribution Breach
Use of Kitzerow’s ideas, processes, results, methodology, hypothesis, systems, or framework without appropriate credit.
What the Trademarks Protect
Trademark protection identifies the names Kitzerow uses to distinguish her systems and their source. It protects against unauthorized use of the registered names or confusingly similar marks when that use may create confusion about source, sponsorship, approval, or affiliation.
What the Compilation Copyright Protects
Kitzerow’s work was filed under compilation copyright. The underlying scientific facts, data, mechanisms, and pathways are not claimed as exclusive property. The protected authorship includes original expression and qualifying original selection, coordination, and arrangement within the documented systems and cascade architecture.
as individual scientific facts.
The original compilation and architecture, including the specific selection and arrangement of those elements.
What Attribution Rights Protect
Attribution rights protect authorship and source recognition for Kitzerow’s novel contributions. This includes her original ideas, methods, hypotheses, principles, concepts, terminology, systems, and frameworks. When those contributions are used, discussed, tested, adapted, or developed by others, Kitzerow should be identified and cited as the primary source.
View Kitzerow’s Primary Source List →CSTL E/I Treatment Comparison
Side-by-side framing of Stanford’s Z944 treatment target against Kitzerow’s earlier CSTL E/I mechanism.
Stanford Tested
Stanford tested whether pharmacological modulation of hyperexcitability in the reticular thalamus, a specific node within the cortico-striatal-thalamic loop, could reverse autism-like behaviors in a genetic mouse model. The intervention used Z944 to modulate T-type calcium channel activity and reduce E/I imbalance at the RT node.
Kitzerow Tested
Kitzerow’s framework identified E/I imbalance across the CSTL as a downstream mechanism through which upstream biochemical and genetic pathway dysregulation produces autism traits and behavioral outputs. Stanford’s intervention tests a specific CSTL node rather than the full upstream cascade.
Executive Summary
Condensed readout of the major evaluative patterns reflected in this report.
Stanford targets E/I imbalance in the reticular thalamus, a defined node within the CSTL architecture.
The Z944 intervention supports the functional relevance of E/I imbalance rather than treating it as merely associative.
Stanford’s Neurodiversity Project reached out on November 27, 2023 and requested Kitzerow’s model information.
The study converges on a specific treatment-relevant CSTL node within the mechanism previously articulated by Kitzerow.
Documented Record
Chronological record of Kitzerow’s CSTL mechanism, Stanford’s direct contact, and Stanford’s later publication sequence.
Score Interpretation
Lower scores indicate higher concern. Higher scores indicate stronger evidence for independence.
Detailed Scoring Table
Six-factor report card formatted as a formal evaluation sheet.
Temporal Precedence
Framework predates study
Value: 3 dots — framework predates study.
Why this score: Kitzerow publicly articulated the CSTL E/I link on May 17, 2023, while Stanford’s first public record does not appear until March 22, 2025.
Dissemination Gap
Time from framework release to first public record
Value: 1 dot — dissemination gap greater than 12 months.
Why this score: Time from Kitzerow’s relevant framework release on May 17, 2023 to Stanford’s first public record on March 22, 2025 is approximately 675 days, or about 22 months.
Publication Timeline
Study start to journal submission
Value: 3 dots — insufficient information to determine development timeline.
Why this score: The true study start date is not publicly documented. The earliest available marker is the preprint on March 22, 2025, which aligns with the journal received date. The available data does not allow clear differentiation between a short development cycle and lack of visible records.
Exposure Likelihood
Probability of access to the framework
Value: 1 dot — confirmed contact with the institution.
Why this score: Stanford’s Neurodiversity Project reached out on November 27, 2023, prior to the study being published, requesting information about Kitzerow’s model.
Structural Specificity
Overlap in mechanism, structure, or conclusions
Value: 5 dots — independent hypothesis and methods with converging conclusions.
Why this score: Stanford tested a specific downstream intervention target within the CSTL rather than the full upstream biochemical cascade. E/I imbalance within CSTL circuitry is present, but the treatment focus is narrower and could plausibly arise through independent circuit-level research.
Institutional Response
Response after notification and publication changes
Value: 3 dots — guarded or limited engagement.
Why this score: When sent confirmed prior contact and evidence of structural overlap, Stanford responded through a secured server saying they would look into it, but no follow-through occurred.
Final Interpretation
Bottom-line readout of the overall score pattern.
Interpretation
Stanford’s score pattern concentrates toward the lower middle of the scale because temporal precedence is established, the dissemination window is long, direct contact is documented, the publication timeline is unknown, and the tested treatment mechanism converges on a specific CSTL-linked E/I target previously articulated within Kitzerow’s broader framework.
Studies Referenced in This Framework
The following studies correspond to the mechanisms mapped in the framework and are provided for direct review and comparison.
Studies are listed in relation to the framework components they correspond to.
- ESC models of autism with copy-number variations reveal cell-type-specific translational vulnerability View Study Here
- Tetrahydrobiopterin and Autism Spectrum Disorder: A Systematic Review of a Promising Therapeutic Pathway View Study Here
- Reticular thalamic hyperexcitability drives autism spectrum disorder behaviors in the Cntnap2 model of autism View Study Here
- Imaging Metabotropic Glutamate Receptor 5 and Excitatory Inhibitory Imbalance in Autism View Study Here
- Nitric Oxide-Mediated S-Nitrosylation of TSC2 Drives mTOR Dysregulation across Autism Models View Study Here
- AI-based autism identification from hyperspectral imaging detection of oxidative stress in pediatric red blood cells View Study Here
- Decomposition of phenotypic heterogeneity in autism reveals underlying genetic programs View Study Here
- A 3-hit metabolic signaling model for the core symptoms of autism spectrum disorder View Study Here